I would go for the big bang. I really would. Otherwise, you're going to be left with an iterative process of change, with the provinces still having a role in coverage, and it's going to be complicated.
When the Swedes changed from driving on the left to driving on the right, they couldn't do it incrementally. Sorry, that's a cheap shot.
We already know what those drugs are. We can put it together. We can put that formulary together, essentially at today's price. Then as the new drugs come on, the extra buying power and leverage of that national program, as well as reviewing prices....
We haven't talked at length about that. We've had a lot of experience of adjusting down drug prices that were already on the schedule in Australia, based on the actual cost of treatment as it played out in the community. Through some product listing agreements that can be introduced—difficult to do retrospectively—that risk of the drug actually being more expensive than was thought because of efficacy or their needing higher doses can be shared with the company. That can be written into the agreement. There are different ways that you can manage costs prospectively.
To get to your point, I would go for the full monty.